ARTA
VYNE icon

A.R.T. Advisors’s VYNE Therapeutics VYNE Stock Holding History

A.R.T. Advisors’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-175
Closed -$99K – 1655
2019
Q1 		$99K Buy
+175
New +$84K 0.01% 1174
2018
Q4 		– Sell
-253
Closed -$179K – 1686
2018
Q3 		$179K Sell
253
-187
-43% -$115K 0.01% 1211
2018
Q2 		$257K Buy
+440
New +$342K 0.01% 1159

Other funds holding VYNE

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

A.R.T. Advisors's VYNE Position: Q2 2019 in Review

A.R.T. Advisors sold out of VYNE Therapeutics (VYNE) in Q2 2019, closing a stake of 175 shares — an estimated $99K sold.

A.R.T. Advisors first reported a position in VYNE in Q2 2018 and held it in 3 quarters. The position peaked at $257K in Q2 2018. 58 funds tracked by Wall St. Rank hold VYNE as of Q2 2019.

  • A.R.T. Advisors reported no remaining VYNE Therapeutics position as of Q2 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 175 VYNE Therapeutics shares in Q2 2019, an estimated $99K.
  • A.R.T. Advisors first reported a position in VYNE Therapeutics in Q2 2018 and held it in 3 quarters.
  • A.R.T. Advisors's VYNE Therapeutics position peaked at $257K in Q2 2018.
  • 58 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q2 2019.

Based on A.R.T. Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.